2023~2025年泉州市某院细菌耐药性监测

doi:10.3969/j.issn.1001-8131.2026.05.014

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (659 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To understand the sensitivity and resistance of clinical isolates to common antibiotics in Quanzhou Municipal First Hospital from 2023 to 2025. Methods From January 2023 to December 2025,non-repetitive pathogenic bacteria isolated from various clinical departments of Quanzhou First Hospital were collected.These bacteria were identified and subjected to drug susceptibility analysis using automated instrument methods,mass spectrometry,microbroth dilution,disk diffusion,and E-test methods. Results A total of 18707 nonduplicate isolates were collected for 3 years,including gram-negative bacteria(12478,66.7%)and gram-positive microorganisms(6229,33.3%).The detection rates of S.aureus(MRSA)were 22.4%,teicoplanin(TEC)、Vancomycin(VA)and linezolid(LZD)resistant staphylococci were not isolated.A few vancomycin and LZD resistant strains were identified in Enterococcus.Most of the Enterobacter in our hospital are still highly sensitive to carbapenems.The resistance rate of Acinetobacter baumannii to antibiotics other than polymyxin B(PMB)and tigecycline(TGC)is close to or higher than 30%.Carbapenem-resistant H.influenzae strains were not isolated. Conclusion Surveillance of bacterial resistance for 3 years in our hospital suggests that carbapenem-resistant Enterobacterales and baumanii are still on the rise.It is necessary to stewardship of antimicrobial agents and strengthen hospital infection control.

Key words： Drug Sensitivity Tests Antibiotic Bacterial Resistance Surveillance

Received: 08 May 2026

PACS:

R978.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Chen Xiaoting
	Zhou Jingqi
	Hu Liping
	Zhu Yan

Cite this article:

Chen Xiaoting,Zhou Jingqi,Hu Liping, et al. Surveillance of Bacterial Resistance in a Hospital in Quanzhou from 2023 to 2025[J]. journal1, 2026, 46(5): 49-53.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2026.05.014 OR http://www.hrbyybjb.org.cn/EN/Y2026/V46/I5/49

[1] 王琳,屈妍.多重耐药菌医院感染防控研究进展[J].中国防痨杂志,2025,47(09):1196-1203.
[2] CLSI.Performance Standards for Antimicrobial Suscep-tibility Testing 34th ed.CLSI supplement M100.Wayne,PA:Clinical and Laboratory Standards institute;2024.
[3] 周静琪,陈晓婷,陈雅彬,等.尿培养和血培养结果对尿路感染继发血流感染的预测价值[J].湖北民族大学学报(医学版),2025,42(04):35-40.
[4] U.S.Food and Drug Administration.FDA-identified in-terpretive criteria[EB/OL].[2021-04-12].https://www.fda.gov/drugs/development-resources/tigecycline-injection-products.
[5] 何秀华,朱焱,杨鹏雅,等.2018—2020年泉州市第一医院细菌耐药性监测[J].中国感染与化疗杂志,2022,22(04):454-462.
[6] 郭燕,胡付品,朱德妹,等.2022年CHINET三级医院细菌耐药监测[J].中国感染与化疗杂志,2024,24(03):277-286.
[7] 胡付品,郭燕,朱德妹,等.2023年CHINET中国细菌耐药性监测结果[J].中国感染与化疗杂志,2024,24(03):257-269.
[8] 全国细菌耐药监测网2020—2024年不同等级医院细菌耐药监测报告[J].中国感染控制杂志,2025,24(12):1717-1734.
[9] Wang Q,Wang R,Wang S,et al.Expansion and tran-smission dynamics of high risk carbapenem-resistant Klebsiella pneumoniae subclones in China:an epide-miological,spatial,genomic analysis[J].Drug Resist Updat,2024,74:101083.
[10] Zhou Y,Wu X,Wu C,et al.Emergence of KPC-2 and NDM-5-coproducing hypervirulent carbapenem-resistant Klebsiella pneumoniae with high-risk sequence types ST11 and ST15[J].mSphere,2024,9(1):e0061223.
[11] Li J,Wu W,Wu H,et al.Rapid emergence,transmission,And evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae[J].Microbiol Res,2025,293:128049.
[12] 王柯,王启,杨硕,等. 多碳青霉烯酶肠杆菌目细菌流行趋势与耐药机制研究[J].中华检验医学杂志,2025,48(9):1158-1164.
[13] 刘婷婷,谢小芳,杜鸿.耐碳青霉烯类肠杆菌目细菌药敏表型与产碳青霉烯酶酶型的相关性分析[J].中国抗生素杂志,2024,49(10):1081-1088.
[14] Uddin B M M,Rahman M A,Yeasmin M M,et al.Epidemiology,clinical conditions,pathogenesis and mecha-nism of resistant of Acinetobacter baumannii:A Narrative Review[J].Bangladesh J Med Microbiol,2023,17(2): 88-92.
[15] 张杰,张伟鹏.鲍曼不动杆菌耐药机制及其研究方法[J/OL].中国抗生素杂志,1-13[2026-02-02].https://doi.org/10.13461/j.cnki.cja.007980.